Positive results Phase 1b trial in sarcopenia
Primary and secondary endpoints have been met in this placebo-controlled study in disuse-induced muscle atrophy. RJx-01 was safe and well tolerated and the innovative formulation confirmed excellent pharmacokinetics.
LEARN MORE